FOLD
Amicus Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$14.49
+0.00%Year over year
Reported trailing growth
- Revenue
- +20.0%
- EBITDA
- +83.1%
- EBIT
- +31.8%
- EPS
- +51.0%
- Free cash flow
- +179.7%
- Operating cash flow
- +197.8%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- +24.4%
- EBITDA
- +83.1%
- EBIT
- +38.7%
- Net income
- +51.7%
- EPS
- +51.2%
- Free cash flow
- +179.7%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Dec 1, 2025